|
Books > Science & Mathematics > Biology, life sciences > Cellular biology
|
Buy Now
Senolytics in Disease, Ageing and Longevity (Hardcover, 1st ed. 2020)
Loot Price: R4,001
Discovery Miles 40 010
|
|
|
Senolytics in Disease, Ageing and Longevity (Hardcover, 1st ed. 2020)
Series: Healthy Ageing and Longevity, 11
Expected to ship within 10 - 15 working days
|
This book offers comprehensive information on the new and rapidly
evolving science of identifying and targeting senescent cells, and
on the exciting prospect of new diagnostic and therapeutic
opportunities for stopping, and even reversing, the progression of
disease and the deterioration of the human body due to ageing.
According to recent United Nations data, by 2050 one in six people
worldwide will be older than age 65, with peaks rising to one in
four people in Europe and North America. Remarkably, the number of
persons aged 80 years or older is expected to triple, from 143
million in 2019 to 426 million in 2050. First documented in the
1960s, the concept of cellular senescence as an underlying cause of
ageing has been established in the course of the last decade. Using
genetically engineered mouse models, researchers have demonstrated
that the selective elimination of senescent cells can block and
even reverse a number of age-related dysfunctions and pathologies,
promoting both better health and longer life in the elderly. These
include cardiovascular diseases; neurological disorders; type 1 and
type 2 diabetes; inflammatory diseases; fibrosis; geriatric
syndromes; chronic diseases resulting in organ dysfunction; the
integrity of the musculoskeletal system; and cancer. Some senolytic
agents have already progressed into trials. These include UBX0101
for the treatment of osteoarthritis (now in phase II), a cocktail
of dasatinib and quercetin for the management of idiopathic
pulmonary fibrosis and chronic kidney disease, and ABT-263 in
combination with senescence-inducing chemotherapies for the
treatment of advanced solid tumours. In addition, the book
discusses pathways to early phase clinical trials and translational
approaches in medicine and ageing, highlighting new opportunities
as well as current limitations, challenges and alternatives. Given
its scope, it will benefit a broad audience of advanced educators,
researchers, graduate students and practitioners.
General
Is the information for this product incomplete, wrong or inappropriate?
Let us know about it.
Does this product have an incorrect or missing image?
Send us a new image.
Is this product missing categories?
Add more categories.
Review This Product
No reviews yet - be the first to create one!
|
You might also like..
|
Welcome to Loot.co.za!
Sign in / Register |Wishlists & Gift Vouchers |Help | Advanced search
